Antagonists of CXC chemokine receptor 4 (CXCR4) including AMD3100 induce peripheral mobilization of hematopoietic stem cells and have been approved for medical use. (BM) microenvironment [4]. SDF-1 only offers negligible effects within the proliferation of both normal and malignant hematopoietic cells TCS ERK 11e (VX-11e) [5] but the SDF-1/CXCR4 axis offers been shown to be… Continue reading Antagonists of CXC chemokine receptor 4 (CXCR4) including AMD3100 induce peripheral